NetWorth
LeaderPortfolio
Arkin
M
Rank #2492
ISRAEL•Healthcare•Pharmaceuticals

Mori Arkin

Net Worth
$1.583B
-0.11% (24h)
Mori Arkin is an Israeli billionaire and entrepreneur, primarily known for his significant contributions to the pharmaceutical industry. Born in 1952, Arkin's career began in 1972 assisting his father in a pharmaceutical distribution business. He transformed the family business into Agis Industries, a major player in generic pharmaceuticals. In 2005, he sold Agis to Perrigo for $390 million. Arkin then founded Arkin Holdings and Arkin Capital, a multi-stage investment manager, expanding into biotech, healthcare, and related sectors. His estimated net worth as of March 2026 is $1.5 billion. Arkin's career is marked by strategic exits, successful investments, and a commitment to philanthropic endeavors through the Arkin Family Foundation.

How to read Mori Arkin's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Mori Arkin, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $1.583B alongside global rank #2492, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (ISRAEL) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life

Moshe "Mori" Arkin was born in Ramat Gan, Israel, in 1952. His parents were Russian immigrants who owned a pharmacy, which provided a modest entrepreneurial foundation. Arkin's father, Ziama Arkin, founded Agis Commercial Agencies in 1961, a pharmaceutical importer.

Rise to Success

Arkin began his career in 1972, assisting his father in their pharmaceutical distribution business. In 1983, he transformed it into Agis Industries, which became a leading generic pharmaceutical manufacturer, particularly in topical dermatological products. Arkin's strategic acumen led to the 2005 sale of Agis to Perrigo for $390 million. Following this, he established Arkin Capital in 2009, an investment platform for life sciences ventures.

Key Business Strategies

Arkin's business strategy is characterized by industry specialization, strategic exits, and reinvestment in high-growth niches. A significant move was the 2004 sale of Agis Industries, which provided capital for subsequent ventures. He retained majority ownership of Sol-Gel Technologies, a dermatology-focused firm, after its 2018 IPO, underscoring his focus on long-term value creation.

Philanthropy

Arkin, along with his wife Doris, established the Arkin Family Foundation in 2011. The foundation supports initiatives in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

Career Timeline

2011

Arkin Family Foundation

Established Arkin Family Foundation, focused on education, healthcare, civil rights, and Jewish-Arab coexistence

2018

Sol-Gel Technologies IPO

Oversaw the public offering of Sol-Gel Technologies on Nasdaq.

2009

Founded Arkin Capital

Established an investment firm focused on life sciences.

2005

Sold Agis Industries

Sold Agis to Perrigo for $390 million.

1983

Founded Agis Industries

Transformed the family business into a generic pharmaceutical manufacturer.

1972

Joined Family Business

Began assisting his father in a pharmaceutical distribution company.

Philanthropic Impact

EducationUndisclosed

Ziama Arkin Parent and Infant Relations (PAIR) Institute

Supported the establishment of the PAIR Institute at Reichman University, focusing on parent-infant relationships.

Key Business Ventures & Holdings

CompanyStakeValue
Sol-Gel Technologies62.00%$0.1M

Net Worth History

In-Depth Analysis

Early Life

Moshe "Mori" Arkin was born in Ramat Gan, Israel, in 1952. His parents were Russian immigrants who owned a pharmacy, which provided a modest entrepreneurial foundation. Arkin's father, Ziama Arkin, founded Agis Commercial Agencies in 1961, a pharmaceutical importer.

Rise to Success

Arkin began his career in 1972, assisting his father in their pharmaceutical distribution business. In 1983, he transformed it into Agis Industries, which became a leading generic pharmaceutical manufacturer, particularly in topical dermatological products. Arkin's strategic acumen led to the 2005 sale of Agis to Perrigo for $390 million. Following this, he established Arkin Capital in 2009, an investment platform for life sciences ventures.

Key Business Strategies

Arkin's business strategy is characterized by industry specialization, strategic exits, and reinvestment in high-growth niches. A significant move was the 2004 sale of Agis Industries, which provided capital for subsequent ventures. He retained majority ownership of Sol-Gel Technologies, a dermatology-focused firm, after its 2018 IPO, underscoring his focus on long-term value creation.

Philanthropy

Arkin, along with his wife Doris, established the Arkin Family Foundation in 2011. The foundation supports initiatives in education, arts and culture, welfare, healthcare, civil rights, and Jewish-Arab coexistence.

Data Sources & Methodology

Figures for Mori Arkin are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom